Regulatory review is the last major development hurdle that must be
passed by a new medicine before it reaches the market. At a time when
pharmaceutical companies are reviewing their R&D strategies, and
attempting to reduce drug development times, it is extremely important
that the review process is made as efficient as possible. The 11th CMR
Workshop, held in September 1995, provided the opportunity for
regulatory authority and industry personnel from Europe, North America,
Australia and Japan to openly discuss views and exchange experiences on
the subject of improving the review process. The proceedings of this
meeting provide a comprehensive overview of the current review process
around the world. The contributors describe the present situation and
highlight company strategies and regulatory initiatives to improve the
review process. This volume also summarises the suggestions that were
developed by the participants, covering many facets of this process,
including the quality and size of the dossier, dialogue, submission
strategies, feedback and the response to questions.